Loading clinical trials...
Loading clinical trials...
A 24-Week, Multicenter, Randomized, Double-blind, Placebo-Controlled, Add-on, Parallel-Group Study to Assess the Effect of Rasagiline on Cognition in Patients With Parkinson's Disease
Conditions
Interventions
Rasagiline
Placebo
Locations
40
United States
Teva Investigational Site 036
Birmingham, Alabama, United States
Teva Investigational Site 047
Sun City, Arizona, United States
Teva Investigational Site 004
Irvine, California, United States
Teva Investigational Site 016
La Jolla, California, United States
Teva Investigational Site 042
Long Beach, California, United States
Teva Investigational Site 041
San Bernardino, California, United States
Start Date
November 1, 2012
Primary Completion Date
January 1, 2015
Completion Date
January 1, 2015
Last Updated
November 9, 2021
NCT07330258
NCT06508801
NCT07384429
NCT02119611
NCT07310264
NCT07216976
Lead Sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions